#3

JC13 H

2 0 MAR 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

John Alexander Edgar

Title:

ANTI CANCER AGENT AND METHOD OF TREATMENT OF

CANCER

Appl. No.:

Unassigned

Filing Date:

03/20/2002

Examiner:

Unassigned

Art Unit:

Unassigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.56

Commissioner for Patents Box PATENT APPLICATION Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

Atty. Dkt. No. 025217-0104

RELEVANCE OF EACH DOCUMENT

The foregoing documents came to Applicant's attention during a search of the corresponding International application. A copy of the International Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Stephen A. Bent

Attorney for Applicant Registration No. 29,768

11 /ichile 11/1/mlen Reg No. 34.717

Date March 20, 2002

FOLEY & LARDNER

Customer Number: 22428

22428

Telephone: (202) 672-5404

Facsimile.

(202) 672 5399

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449B/PTO

> INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: March 20, 2002

(use as many sheets as necessary) 2 of

Sheet

C	om if Knowi 11, 1188078
Application Number	Unassigned
Filing Date	03/20/2002
First Named Inventor	John Alexander Edgar
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	025217-0104

0	U.S. PATENT DOCUMENTS						
Examiner	Cite	O. Number Code ² (if		Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*	No. ¹			Cited Document	Cited Document MM-DD-YYYY		
İ					· «Y» ·		
			•			. « -	
, i			-			· • - •	
j				· ·		•	
4						8	
						-	
1					•	· - · - · ·	
1	· .					- · · · · · · · · · · · · · · · · · · ·	
						· ·	
						· · · · · · · · · · · · · · · · · · ·	
I	•			·		_	
ŀ							
į			•		•		

				F	DREIGN PATENT DOCUMEN	ITS		
Examiner Initials*	Cite No. ¹	Office	oreign Patent D 3 Number ⁴	Oocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	A1	AU	64916/90		Davies & Collison	05/02/1991		
-				٠		•		
					-			•
						•		+
				•		· ·		•

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s) publisher, city and/or country where published.	+

Examiner		Date
Signature		Considered

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3) ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible ⁴Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

nu <u>mber.</u>					
	Substitute for form	1449B/PTO		Comp. f Known	
	INFORMATION DIS	SCLOSURE	Application Number	Unassigned	
	STATEMENT BY A	APPLICANT	Filing Date	03/20/2002	
	Date Submitted: Ma	rch 18, 2002	First Named Inventor	John Alexander Edgar	
'	Date Submitted, Ma	1011 10, 2002	Group Art Unit	Unassigned	
(L	se as many sheets	as necessary)	Examiner Name	Unassigned	
Sheet	2	of 2	Attorney Docket Number	025217-0104	

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	16
	A2	VAN ASWEGEN et al., "Influence of Phomopsin and Ivalin on Steroid-Hormone Binding and Growth of MCF-7 Human Breast Cancer Cells", J. of Toxicology & Environmental Health, 1985, pp. 13-23, Vol. 16, No. 1, Hemisphere Publishing Corporation.	!
	A3 .	LI et al., "Interaction of Phomopsin A with Porcine Brain Tubulin", Biochemical Pharmacology, 1992, pp. 219-224, Vol. 43, No. 2, Pergamon Press.	
	A4 .	TAKAHASHI et al., "Synthetic Study of Ustiloxin Analogs: Benzylic Oxidation of 13-Membered Cyclic Peptide by Lead Tetraacetate", Heterocycles, 1998, pp. 163-166, Vol. 47, No. 1, Inst. Of Molecular and Cellular Biosciences (IMCB), Univ. of Tokyo.	
			1
			
:			· · · -
			
			-• • • •
:			
			· -•
			:

1	Examiner
l	Signature

Date Considered

^{*}EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number "See attached Kinds of U.S. Patent Documents." Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible." Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.